Key facts
- Leitekang (Suzhou) Biopharmaceuticals’s last known valuation is $76.8M (Mar 2026).
- It has raised $4.3M; the latest was Later Stage VC ($4.3M) in Mar 2026.
- Notable investors include Highlight Capital, BrightGene Bio-Medical Technology Company, Laurel Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Leitekang (Suzhou) Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Leitekang (Suzhou) Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leitekang (Suzhou) Biopharmaceuticals
Developer of innovative biologic drugs designed to address malignant tumors and autoimmune diseases. The company offers proprietary antibody fusion proteins, bispecific antibodies, and novel ADC technologies, enabling medical researchers and healthcare providers to develop safe and effective treatments with global intellectual property rights.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Leitekang (Suzhou) Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leitekang (Suzhou) Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leitekang (Suzhou) Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.